Paper Details

  1. Home
  2. Paper Details

Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.

Author: AkaberiDario, BergforsAssar, DanielssonAstrid, DubergAnn-Sofi, Gangsøy KristiansenMagnhild, GollRasmus, GuttebergTore, KilengHege, KjellinMidori, LannergårdAnders, LennerstrandJohan, WesslénLars

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This multi-center study investigated the effects of baseline NS3-RASs and clinically relevant NS5A-RASs in patients with HCV genotype 1a infection on treatment outcome.
Paper Details　
Original Abstract of the Article :
Resistance-associated substitutions (RASs) may impair treatment response to direct-acting antivirals (DAA) in hepatitis C virus (HCV) treatment. We investigated the effects of baseline NS3-RASs (Q80K and R155K) and clinically relevant NS5A-RASs in patients with HCV genotype (GT) 1a infection on trea...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/00365521.2018.1511824

データ提供：米国国立医学図書館（NLM）

Personalized Treatment for Hepatitis C: A Targeted Approach

The field of virology is constantly seeking new ways to combat viral infections, and this study explores the impact of personalized treatment strategies for hepatitis C. The researchers investigated the effects of resistance-associated substitutions (RASs) in the NS3 and NS5A proteins of the hepatitis C virus (HCV) on treatment outcomes. They found that baseline RASs can affect the effectiveness of direct-acting antiviral (DAA) therapies. This study provides valuable insights into the importance of considering individual genetic variations when developing treatment plans for HCV infection.

Tailoring Treatment for Hepatitis C

This research demonstrates the benefits of personalized treatment approaches for hepatitis C. By considering individual genetic variations, we can optimize treatment strategies and improve outcomes for patients.

Staying One Step Ahead of Hepatitis C

Just like a camel navigates the desert with its keen sense of direction, we need to stay one step ahead of hepatitis C. This study underscores the importance of considering individual factors when developing treatment plans.

Dr.Camel's Conclusion

This study emphasizes the importance of personalized approaches to hepatitis C treatment. By considering individual genetic variations, we can develop more effective and targeted strategies for combating this viral infection. Just like a camel adapts to the changing desert environment, we can adapt our treatment approaches to create better outcomes for individuals battling hepatitis C.

Date :
  1. Date Completed 2019-04-16
  2. Date Revised 2022-01-10
Further Info :

Pubmed ID

30394152

DOI: Digital Object Identifier

10.1080/00365521.2018.1511824

Related Literature

Article Analysis
・Effects of simeprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.